ZYLOXTB Buys Back 150,000 H-Shares, Treasury Stock Rises to 7.45 Million

Bulletin Express18:05

Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange.

• Transaction details – Trading date: 27 March 2026 – Method: On-market repurchase – Price range: HKD 23.66 – HKD 24.10 per share – Volume-weighted average price: HKD 23.92 per share – Aggregate consideration: HKD 3.59 million

• Impact on share capital – Issued shares (excluding treasury shares) declined from 329.05 million to 328.90 million, a 0.04% reduction. – Treasury shares increased from 7.30 million to 7.45 million. – Total issued shares remained unchanged at 336.35 million.

• Repurchase mandate utilisation – Authorised limit (approved 30 May 2025): 31.96 million shares. – Cumulative repurchased to date: 4.64 million shares, equal to 1.42% of the shares outstanding when the mandate was granted. – A 30-day moratorium on new share issues or treasury share disposals applies until 26 April 2026.

The board confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128467446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128467446","market":"hk","top_or_hot":-1,"title":"ZYLOXTB Buys Back 150,000 H-Shares, Treasury Stock Rises to 7.45 Million","media":"Bulletin Express","content":"<p>Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n  – Trading date: 27 March 2026  \n  – Method: On-market repurchase  \n  – Price range: HKD 23.66 – HKD 24.10 per share  \n  – Volume-weighted average price: HKD 23.92 per share  \n  – Aggregate consideration: HKD 3.59 million</p>\n<p>• Impact on share capital  \n  – Issued shares (excluding treasury shares) declined from 329.05 million to 328.90 million, a 0.04% reduction.  \n  – Treasury shares increased from 7.30 million to 7.45 million.  \n  – Total issued shares remained unchanged at 336.35 million.</p>\n<p>• Repurchase mandate utilisation  \n  – Authorised limit (approved 30 May 2025): 31.96 million shares.  \n  – Cumulative repurchased to date: 4.64 million shares, equal to 1.42% of the shares outstanding when the mandate was granted.  \n  – A 30-day moratorium on new share issues or treasury share disposals applies until 26 April 2026.</p>\n<p>The board confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZYLOXTB Buys Back 150,000 H-Shares, Treasury Stock Rises to 7.45 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZYLOXTB Buys Back 150,000 H-Shares, Treasury Stock Rises to 7.45 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-27 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n  – Trading date: 27 March 2026  \n  – Method: On-market repurchase  \n  – Price range: HKD 23.66 – HKD 24.10 per share  \n  – Volume-weighted average price: HKD 23.92 per share  \n  – Aggregate consideration: HKD 3.59 million</p>\n<p>• Impact on share capital  \n  – Issued shares (excluding treasury shares) declined from 329.05 million to 328.90 million, a 0.04% reduction.  \n  – Treasury shares increased from 7.30 million to 7.45 million.  \n  – Total issued shares remained unchanged at 336.35 million.</p>\n<p>• Repurchase mandate utilisation  \n  – Authorised limit (approved 30 May 2025): 31.96 million shares.  \n  – Cumulative repurchased to date: 4.64 million shares, equal to 1.42% of the shares outstanding when the mandate was granted.  \n  – A 30-day moratorium on new share issues or treasury share disposals applies until 26 April 2026.</p>\n<p>The board confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02190","symbol_name":"归创通桥","start_time":0,"source_url":"","article_id":"1128467446","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128467446","pubTimestamp":1774605957,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange. • Transaction details     – Trading...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02190":"归创通桥"},"translate_title":"ZYLOXTB回购15万股H股库存股升至745万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share repurchase on 27 March 2026, acquiring 150,000 H-shares on the Hong Kong Stock Exchange.\n• Transaction details  \n  – Trading date: 27 March 2026  \n  – Method: On-market repurchase  \n  – Price range: HKD 23.66 – HKD 24.10 per share  \n  – Volume-weighted average price: HKD 23.92 per share  \n  – Aggregate consideration: HKD 3.59 million\n• Impact on share capital  \n  – Issued shares (excluding treasury shares) declined from 329.05 million to 328.90 million, a 0.04% reduction.  \n  – Treasury shares increased from 7.30 million to 7.45 million.  \n  – Total issued shares remained unchanged at 336.35 million.\n• Repurchase mandate utilisation  \n  – Authorised limit (approved 30 May 2025): 31.96 million shares.  \n  – Cumulative repurchased to date: 4.64 million shares, equal to 1.42% of the shares outstanding when the mandate was granted.  \n  – A 30-day moratorium on new share issues or treasury share disposals applies until 26 April 2026.\nThe board confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128467446","isCrawlerRequest":true}